# Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

> **NCT00569010** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Ara-C

## Key facts

- **NCT ID:** NCT00569010
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2012-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00569010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00569010, "Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00569010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*